Shortening duration of direct-acting antiviral therapy for chronic hepatitis C could provide cost savings, reduce medication exposure, and foster adherence and treatment completion in special populations. The current analysis indicates that measuring hepatitis C virus at baseline and on days 7 and 14 of therapy can identify patients for shortening therapy duration.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045946 | PMC |
| http://dx.doi.org/10.1093/ofid/ofac157 | DOI Listing |
Publication Analysis
Top Keywords
therapy chronic
8
chronic hepatitis
8
modeling-based response-guided
4
response-guided daa
4
therapy
4
daa therapy
4
hepatitis identify
4
identify individuals
4
individuals shortening
4
shortening treatment
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!